3. NET LOSS PER SHARE

Basic and diluted net loss per share have been computed by dividing the net loss by the weighted-average number of common shares outstanding during the period, without consideration of common share equivalents as their effect would have been antidilutive.

The following tables set forth the computation of the Company’s basic and diluted net loss per share (in thousands, except shares and per share data):

	Three Months Ended March 31,
	2018			2017
Numerator:
Net loss attributable to CareDx, Inc. used to compute basic and diluted net loss per share	$	(8,969	)	$	(5,562	)
Denominator:
Weighted-average shares used to compute basic and diluted net loss per share attributable to CareDx, Inc.		29,615,441			21,343,782
Net loss per share attributable to CareDx, Inc.:
Basic and diluted	$	(0.30	)	$	(0.26	)

The following potentially dilutive securities have been excluded from diluted net loss per share, because their effect would be antidilutive:

	March 31,
	2018		2017
Shares of common stock subject to outstanding options		1,940,010		1,881,416
Shares of common stock subject to outstanding common stock warrants		3,633,565		4,509,926
Shares of common stock subject to convertible notes		—		6,092,105
Shares of common stock subject to contingent consideration		227,845		227,845
Restricted stock units		441,804		440,910
Total common stock equivalents		6,243,224		13,152,202

On October 10, 2017, the Company completed an underwritten public offering (the “2017 Public Offering”), pursuant to which the Company issued and sold an aggregate of 4,992,840 shares. During 2017 and the three months ended March 31, 2018, 6,415,039 shares of common stock subject to convertible notes were issued due to the conversion of the JGB debt.